Analysts/Institutional Investor Meet/Con. Call Updates

July 13, 2026 BSE Limited National Stock Exchange of India Limited Floor 25, P. J. Towers Exchange Plaza Dalal Street, Fort Bandra Kurla Complex Mumbai - 400 001 Bandra (E), Mumbai - 400 051 Scrip Code: 543271 Trading Symbol: JUBLINGREA Dear Sir/Madam, Sub: Schedule for Investor Conference Call for Jubilant Ingrevia Limited – Unaudited Financial Results for the quarter ended June 30, 2026 Pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that the Company is organising a conference call on July 23, 2026, at 05:00 pm (IST), for discussion on the financial performance of the Company for the quarter ended June 30, 2026. Details of the conference call are attached. This is for your information and records. Thanking you, Yours faithfully, For Jubilant Ingrevia Limited Deepanjali Gulati Company Secretary & Compliance Officer Encl.: as above Jubilant Ingrevia Limited 1A, Sector 16A, Noida – 201301, India Tel.: +91 120 4361000 www.jubilantingrevia.com Noida, Monday, July 13, 2026 Conference call on Thursday, July 23, 2026, at 05:00 pm IST The management team of Jubilant Ingrevia Limited (JVL) – an integrated global Specialty Chemicals & CDMO company, will host its conference call for analysts and investors on Thursday, July 23, 2026, at 05:00 pm IST. The call will commence with a brief management discussion on the financial performance for the quarter ended June 30, 2026, followed by an interactive Question & Answer session. Diamond Pass Log-In To enable participants to connect to the conference call without having to wait for an operator, please register at the below mentioned link. Pre-registration: You will receive dial in numbers, passcode and a pin for the concall on the registered email address provided by you. Kindly dial into the call on the Conference Call date and use the passcode & pin to connect to call. Conference Dial-In Numbers + 91 22 6280 1141 Universal Access: + 91 22 7115 8042 USA: 1 866 746 2133 Toll Free Number: UK: 0 808 101 1573 Singapore: 800 101 2045 Hong Kong: 800 964 448 The Audio link will be available on the company website. Please access Audio Link: the link here - https://jubilantingrevia.com/investors/financials/quarterly-results -ENDS – About Jubilant Ingrevia Limited Jubilant Ingrevia Limited is a leading player in Specialty Chemicals & CDMO globally, serving Pharmaceutical, Nutrition, Agrochemical, Consumer, Semiconductor and Industrial customers. It offers customised solutions that are innovative, cost-effective and conform to global quality standards and has a broad portfolio of 130+ products. It has over 45 years of legacy in the chemicals industry and is amongst the top players globally in Pyridine & Picolines, Pyridine derivatives, Acetic Anhydride, Vitamin-B3 and many other products. Jubilant Ingrevia Limited has a fast-growing Custom Development and Manufacturing business (CDMO) serving pharmaceuticals, agrochemicals and semiconductor sectors. The Company serves customers in US, EU, Japan, Middle East, South East Asia and other geographies, in addition to domestic market from its 50 plants across 5 manufacturing facilities in India with a workforce of over 2,300 employees. Its three R&D centres employ 150 scientists working on cutting-edge research and innovation. Jubilant Ingrevia Limited is a Responsible Care certified company and ranked highly in global ESG indices such as Ecovadis and Dow Jones Sustainability Index. In 2024, Jubilant Ingrevia Limited was also recognised by the World Economic Forum (WEF) and entered its prestigious Global Lighthouse Network (GLN) for deployment of 4IR technologies. For more information, please visit: www.jubilantingrevia.com For more information please contact: Pavleen Taneja Siddharth Rangnekar / Mit Shah Jubilant Ingrevia Limited CDR India Ph: +91-120 4361000 Ph: +91 97699 19966 / 99201 68314 E-mail: pavleen.taneja@jubl.com E-mail: siddharth@cdr-india.com mit@cdr-india.com Disclaimer: Statements in this document relating to future status, events, or circumstances, including but not limited to statements about plans and objectives, the progress and results of research and development, potential product characteristics and uses, product sales potential and target dates for product launch are forward looking statements based on estimates and the anticipated effects of future events on current and developing circumstances. Such statements are subject to numerous risks and uncertainties and are not necessarily predictive of future results. Actual results may differ materially from those anticipated in the forward-looking statements. Jubilant Ingrevia Limited may, from time to time, make additional written and oral forward-looking statements, including statements contained in the company’s filings with the regulatory bodies and our reports to shareholders. The company assumes no obligation to update forward- looking statements to reflect actual results, changed assumptions or other factors.